169 related articles for article (PubMed ID: 37400844)
1. Phase 1 dose-escalation study to evaluate the safety, tolerability, pharmacokinetics, and anti-tumor activity of FCN-159 in adults with neurofibromatosis type 1-related unresectable plexiform neurofibromas.
Hu X; Li W; Zeng K; Xu Z; Li C; Kang Z; Li S; Huang X; Han P; Lin H; Hui AM; Tan Y; Diao L; Li B; Wang X; Wu Z; Lin X
BMC Med; 2023 Jul; 21(1):230. PubMed ID: 37400844
[TBL] [Abstract][Full Text] [Related]
2. Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
Fisher MJ; Shih CS; Rhodes SD; Armstrong AE; Wolters PL; Dombi E; Zhang C; Angus SP; Johnson GL; Packer RJ; Allen JC; Ullrich NJ; Goldman S; Gutmann DH; Plotkin SR; Rosser T; Robertson KA; Widemann BC; Smith AE; Bessler WK; He Y; Park SJ; Mund JA; Jiang L; Bijangi-Vishehsaraei K; Robinson CT; Cutter GR; Korf BR; ; Blakeley JO; Clapp DW
Nat Med; 2021 Jan; 27(1):165-173. PubMed ID: 33442015
[TBL] [Abstract][Full Text] [Related]
3. A first-in-human, phase 1a dose-escalation study of the selective MEK1/2 inhibitor FCN-159 in patients with advanced NRAS-mutant melanoma.
Mao L; Guo J; Zhu L; Jiang Y; Yan W; Zhang J; Hui AM; Yang Y; Diao L; Tan Y; Zhao H; Jiang Y; Wu Z; Si L
Eur J Cancer; 2022 Nov; 175():125-135. PubMed ID: 36113242
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
Widemann BC; Babovic-Vuksanovic D; Dombi E; Wolters PL; Goldman S; Martin S; Goodwin A; Goodspeed W; Kieran MW; Cohen B; Blaney SM; King A; Solomon J; Patronas N; Balis FM; Fox E; Steinberg SM; Packer RJ
Pediatr Blood Cancer; 2014 Sep; 61(9):1598-602. PubMed ID: 24753394
[TBL] [Abstract][Full Text] [Related]
5. Activity of Selumetinib in Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Dombi E; Baldwin A; Marcus LJ; Fisher MJ; Weiss B; Kim A; Whitcomb P; Martin S; Aschbacher-Smith LE; Rizvi TA; Wu J; Ershler R; Wolters P; Therrien J; Glod J; Belasco JB; Schorry E; Brofferio A; Starosta AJ; Gillespie A; Doyle AL; Ratner N; Widemann BC
N Engl J Med; 2016 Dec; 375(26):2550-2560. PubMed ID: 28029918
[TBL] [Abstract][Full Text] [Related]
6. Characteristics of children enrolled in treatment trials for NF1-related plexiform neurofibromas.
Kim A; Gillespie A; Dombi E; Goodwin A; Goodspeed W; Fox E; Balis FM; Widemann BC
Neurology; 2009 Oct; 73(16):1273-9. PubMed ID: 19841379
[TBL] [Abstract][Full Text] [Related]
7. NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Weiss BD; Wolters PL; Plotkin SR; Widemann BC; Tonsgard JH; Blakeley J; Allen JC; Schorry E; Korf B; Robison NJ; Goldman S; Vinks AA; Emoto C; Fukuda T; Robinson CT; Cutter G; Edwards L; Dombi E; Ratner N; Packer R; Fisher MJ
J Clin Oncol; 2021 Mar; 39(7):797-806. PubMed ID: 33507822
[TBL] [Abstract][Full Text] [Related]
8. A Review of Selumetinib in the Treatment of Neurofibromatosis Type 1-Related Plexiform Neurofibromas.
Anderson MK; Johnson M; Thornburg L; Halford Z
Ann Pharmacother; 2022 Jun; 56(6):716-726. PubMed ID: 34541874
[TBL] [Abstract][Full Text] [Related]
9. Phase I trial and pharmacokinetic study of sorafenib in children with neurofibromatosis type I and plexiform neurofibromas.
Kim A; Dombi E; Tepas K; Fox E; Martin S; Wolters P; Balis FM; Jayaprakash N; Turkbey B; Muradyan N; Choyke PL; Reddy A; Korf B; Widemann BC
Pediatr Blood Cancer; 2013 Mar; 60(3):396-401. PubMed ID: 22961690
[TBL] [Abstract][Full Text] [Related]
10. Treatment decisions and the use of MEK inhibitors for children with neurofibromatosis type 1-related plexiform neurofibromas.
Armstrong AE; Belzberg AJ; Crawford JR; Hirbe AC; Wang ZJ
BMC Cancer; 2023 Jun; 23(1):553. PubMed ID: 37328781
[TBL] [Abstract][Full Text] [Related]
11. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial.
Robertson KA; Nalepa G; Yang FC; Bowers DC; Ho CY; Hutchins GD; Croop JM; Vik TA; Denne SC; Parada LF; Hingtgen CM; Walsh LE; Yu M; Pradhan KR; Edwards-Brown MK; Cohen MD; Fletcher JW; Travers JB; Staser KW; Lee MW; Sherman MR; Davis CJ; Miller LC; Ingram DA; Clapp DW
Lancet Oncol; 2012 Dec; 13(12):1218-24. PubMed ID: 23099009
[TBL] [Abstract][Full Text] [Related]
12. Selumetinib in Children with Inoperable Plexiform Neurofibromas.
Gross AM; Wolters PL; Dombi E; Baldwin A; Whitcomb P; Fisher MJ; Weiss B; Kim A; Bornhorst M; Shah AC; Martin S; Roderick MC; Pichard DC; Carbonell A; Paul SM; Therrien J; Kapustina O; Heisey K; Clapp DW; Zhang C; Peer CJ; Figg WD; Smith M; Glod J; Blakeley JO; Steinberg SM; Venzon DJ; Doyle LA; Widemann BC
N Engl J Med; 2020 Apr; 382(15):1430-1442. PubMed ID: 32187457
[TBL] [Abstract][Full Text] [Related]
13. Pediatric PK/PD Phase I Trial of Pexidartinib in Relapsed and Refractory Leukemias and Solid Tumors Including Neurofibromatosis Type I-Related Plexiform Neurofibromas.
Boal LH; Glod J; Spencer M; Kasai M; Derdak J; Dombi E; Ahlman M; Beury DW; Merchant MS; Persenaire C; Liewehr DJ; Steinberg SM; Widemann BC; Kaplan RN
Clin Cancer Res; 2020 Dec; 26(23):6112-6121. PubMed ID: 32943455
[TBL] [Abstract][Full Text] [Related]
14. Response of NF1-related plexiform neurofibroma to high-dose carboplatin.
Hummel T; Anyane-Yeboa A; Mo J; Towbin A; Weiss B
Pediatr Blood Cancer; 2011 Mar; 56(3):488-90. PubMed ID: 21225936
[TBL] [Abstract][Full Text] [Related]
15. Long-term safety and efficacy of selumetinib in children with neurofibromatosis type 1 on a phase 1/2 trial for inoperable plexiform neurofibromas.
Gross AM; Dombi E; Wolters PL; Baldwin A; Dufek A; Herrera K; Martin S; Derdak J; Heisey KS; Whitcomb PM; Steinberg SM; Venzon DJ; Fisher MJ; Kim A; Bornhorst M; Weiss BD; Blakeley JO; Smith MA; Widemann BC
Neuro Oncol; 2023 Oct; 25(10):1883-1894. PubMed ID: 37115514
[TBL] [Abstract][Full Text] [Related]
16. A phase 2 study of trametinib for patients with pediatric glioma or plexiform neurofibroma with refractory tumor and activation of the MAPK/ERK pathway: TRAM-01.
Perreault S; Larouche V; Tabori U; Hawkin C; Lippé S; Ellezam B; Décarie JC; Théoret Y; Métras MÉ; Sultan S; Cantin É; Routhier MÈ; Caru M; Legault G; Bouffet É; Lafay-Cousin L; Hukin J; Erker C; Jabado N
BMC Cancer; 2019 Dec; 19(1):1250. PubMed ID: 31881853
[TBL] [Abstract][Full Text] [Related]
17. Plexiform neurofibroma: shedding light on the investigational agents in clinical trials.
Acar S; Armstrong AE; Hirbe AC
Expert Opin Investig Drugs; 2022 Jan; 31(1):31-40. PubMed ID: 34932916
[TBL] [Abstract][Full Text] [Related]
18. Phase I trial and pharmacokinetic study of the farnesyltransferase inhibitor tipifarnib in children with refractory solid tumors or neurofibromatosis type I and plexiform neurofibromas.
Widemann BC; Salzer WL; Arceci RJ; Blaney SM; Fox E; End D; Gillespie A; Whitcomb P; Palumbo JS; Pitney A; Jayaprakash N; Zannikos P; Balis FM
J Clin Oncol; 2006 Jan; 24(3):507-16. PubMed ID: 16421428
[TBL] [Abstract][Full Text] [Related]
19. Population pharmacokinetics and exposure-response of selumetinib and its N-desmethyl metabolite in pediatric patients with neurofibromatosis type 1 and inoperable plexiform neurofibromas.
Schalkwijk S; Zhou L; Cohen-Rabbie S; Jain L; Freshwater T; So K; He Z; Gioni I; Tomkinson H; Vishwanathan K; Zhou D
Cancer Chemother Pharmacol; 2021 Aug; 88(2):189-202. PubMed ID: 33903938
[TBL] [Abstract][Full Text] [Related]
20. Selumetinib for plexiform neurofibromas in neurofibromatosis type 1: a single-institution experience.
Espírito Santo V; Passos J; Nzwalo H; Carvalho I; Santos F; Martins C; Salgado L; Silva CE; Vinhais S; Vilares M; Salgado D; Nunes S
J Neurooncol; 2020 Apr; 147(2):459-463. PubMed ID: 32108293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
